These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24050312)

  • 1. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.
    Oh CK; Leigh R; McLaurin KK; Kim K; Hultquist M; Molfino NA
    Respir Res; 2013 Sep; 14(1):93. PubMed ID: 24050312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.
    Parker JM; Oh CK; LaForce C; Miller SD; Pearlman DS; Le C; Robbie GJ; White WI; White B; Molfino NA;
    BMC Pulm Med; 2011 Feb; 11():14. PubMed ID: 21356110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
    N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
    Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
    N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
    Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
    N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
    N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
    Busse WW; Maspero JF; Rabe KF; Papi A; Wenzel SE; Ford LB; Pavord ID; Zhang B; Staudinger H; Pirozzi G; Amin N; Akinlade B; Eckert L; Chao J; Graham NMH; Teper A
    Adv Ther; 2018 May; 35(5):737-748. PubMed ID: 29725983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
    Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
    Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
    Lemiere C; Taillé C; Lee JK; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Liu MC
    Respir Res; 2021 Jun; 22(1):184. PubMed ID: 34158028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
    Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
    Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.
    Brightling CE; Nair P; Cousins DJ; Louis R; Singh D
    N Engl J Med; 2021 Oct; 385(18):1669-1679. PubMed ID: 34706172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.